#ASCO19: Hey Pfizer, Novartis is going after your blockbuster cancer franchise — and they have positive OS data
CHICAGO — Novartis came to ASCO playing catchup on the breast cancer front. And they’re leaving with a major advance for the campaign.
In an update on their drug Kisqali combined with endocrine therapy, researchers highlighted a 70.2% survival rate among pre-menopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer 42 months after treatment began. That’s significantly better — with a 27% drop in the risk of death — than the former standard of care, where 46% of patients in the Monaleesa-7 control arm were still alive.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 67,300+ biopharma pros reading Endpoints daily — and it's free.